Obesity outweighs protection conferred by adjuvanted influenza vaccination

mBio

Volumn 7, Issue 4, 2016, Pages

  Karlsson, Erik A ^a   Hertz, Tomer ^b,c   Johnson, Cydney ^a   Mehle, Andrew ^d   Krammer, Florian ^e   Schultz Cherry, Stacey ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c USA   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; SIALIDASE; VIRUS ANTIGEN; ALPHA TOCOPHEROL; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; ASO3B ADJUVANT; DRUG COMBINATION; INFLUENZA VIRUS HEMAGGLUTININ; NA PROTEIN, INFLUENZA A VIRUS; POLYSORBATE; SQUALENE; VIRAL PROTEIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; INFLUENZA; INFLUENZA A VIRUS (H7N9); INFLUENZA VACCINATION; LEAN BODY WEIGHT; MORTALITY; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SEROCONVERSION; VIRUS LOAD; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; DRUG COMBINATION; HUMAN; IMMUNOLOGY; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MOUSE MUTANT; RESPIRATORY SYSTEM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ALPHA-TOCOPHEROL; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE, INBRED C57BL; MICE, OBESE; NEURAMINIDASE; OBESITY; POLYSORBATES; RESPIRATORY SYSTEM; SQUALENE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD; VIRAL PROTEINS;

EID: 84986558175     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01144-16     Document Type: Article

References (46)

1. Morgan OW, Bramley A, Fowlkes A, Freedman DS, Taylor TH, Gargiullo P, Belay B, Jain S, Cox C, Kamimoto L, Fiore A, Finelli L, Olsen SJ, Fry AM 2010. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS One 5:e9694. http://dx.doi.org/10.1371/journal.pone.0009694
2. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, Vugia D, Harriman K, Matyas B, Glaser CA, Samuel MC, Rosenberg J, Talarico J, Hatch D, California Pandemic (H1N1) Working Group 2009. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 302:1896-1902. http://dx.doi.org/10.1001/jama.2009.1583
3. Liu B, Havers F, Chen E, Yuan Z, Yuan H, Ou J, Shang M, Kang K, Liao K, Liu F, Li D, Ding H, Zhou L, Zhu W, Ding F, Zhang P, Wang X, Yao J, Xiang N, Zhou S, Liu X, Song Y, Su H, Wang R, Cai J, Cao Y, Wang X, Bai T, Wang J, Feng Z, Zhang Y, Widdowson M-A, Li Q 2014. Risk factors for influenza A(H7N9) disease—China, 2013. Clin Infect Dis 59: 787-794. http://dx.doi.org/10.1093/cid/ciu423
4. World Health Organization 2015. Obesity and overweight. Fact sheet 311. WHO, Geneva, Switzerland. Accessed 20 February 2016. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 20 February 2015
5. Fiore AE, Bridges CB, Cox NJ 2009. Seasonal influenza vaccines. Curr Top Microbiol Immunol 333:43-82. http://dx.doi.org/10.1007/978-3-540-92165-3_3
6. World Health Organization 2013. Vaccine response to the avian influenza A(H7N9) outbreak—step 1: development and distribution of candidate vaccine viruses. WHO, Geneva, Switzerland. http://www.who.int/influenza/vaccines/virus/CandidateVaccineVirusesH7N9_02May13.pdf
7. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Höschler K, Zambon MC 2006. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367:1657-1664. http://dx.doi.org/10.1016/S0140-6736(06)68656-X
8. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354:1343-1351. http://dx.doi.org/10.1056/NEJMoa055778
9. Couch RB, Patel SM, Wade-Bowers CL, Niño D 2012. A randomized clinical trial of an inactivated avian influenzaA(H7N7) vaccine. PLoS One 7:e49704. http://dx.doi.org/10.1371/journal.pone.0049704
10. Even-Or O, Samira S, Ellis R, Kedar E, Barenholz Y 2013. Adjuvanted influenza vaccines. Expert Rev Vaccines 12:1095-1108. http://dx.doi.org/10.1586/14760584.2013.825445
11. Alving CR, Peachman KK, Rao M, Reed SG 2012. Adjuvants for human vaccines. Curr Opin Immunol 24:310-315. http://dx.doi.org/10.1016/j.coi.2012.03.008
12. Wu CY, Chang CY, Ma HH, Wang CW, Chen YT, Hsiao PW, Chang CC, Chan CH, Liu CC, Chen JR 2014. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses. Vaccine 32:4485-4494. http://dx.doi.org/10.1016/j.vaccine.2014.06.043
13. Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, Berry AA, Graham I, Atmar RL, Creech CB, Thomsen IP, Patel SM, Gutierrez AF, Anderson EL, El Sahly HM, Hill H, Noah DL, Bellamy AR 2015. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial. JAMA 314:237-246. http://dx.doi.org/10.1001/jama.2015.7916
14. Wong SS, Kaplan B, Zanin M, Debeauchamp J, Kercher L, Crumpton JC, Seiler P, Sun Y, Tang L, Krauss S, Webster R, Webby RJ 2015. Impact of adjuvants on the immunogenicity and efficacy of split-virion H7N9 vaccine in ferrets. J Infect Dis 212:542-551., http://dx.doi.org/10.1093/infdis/jiv09
15. Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman P, Ince D, Noah DL, Hill H, Bellamy AR, DMID 13-0032 H7N9 Vaccine Study Group 2014. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA 312:1409-1419. http://dx.doi.org/10.1001/jama.2014.12854
16. Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB, Holland LA, Weir S, Noah TL, Beck MA 2012. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes (Lond) 36:1072-1077. http://dx.doi.org/10.1038/ijo.2011.208
17. Park HL, Shim SH, Lee EY, Cho W, Park S, Jeon HJ, Ahn SY, Kim H, Nam JH 2014. Obesity-induced chronic inflammation is associated with the reduced efficacy of influenza vaccine. Hum Vaccin Immunother 10: 1181-1186. http://dx.doi.org/10.4161/hv.28332
18. Kim YH, Kim JK, Kim DJ, Nam JH, Shim SM, Choi YK, Lee CH, Poo H 2012. Diet-induced obesity dramatically reduces the efficacy of a 2009 pandemic H1N1 vaccine in a mouse model. J Infect Dis 205:244-251. http://dx.doi.org/10.1093/infdis/jir731
19. Reber A, Katz J 2013. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines 12:519-536. http://dx.doi.org/10.1586/erv.13.35
20. Finkelstein EA, Khavjou OA, Thompson H, Trogdon JG, Pan L, Sherry B, DietzW 2012. Obesity and severe obesity forecasts through 2030. Am J Prev Med 42:563-570. http://dx.doi.org/10.1016/j.amepre.2011.10.026
21. Breda J, Jewell J, Webber L, Galea G 2015. WHO projections in adults to 2030, abstr WHO.4. Abstr 22nd Eur Congress Obes (ECO2015), Prague, Czech Republic, 6 to 9 May 2015
22. Couch RB, Atmar RL, Franco LM, Quarles JM, Wells J, Arden N, Niño D, Belmont JW 2013. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 207:974-981. http://dx.doi.org/10.1093/infdis/jis935
23. Krammer F, Pica N, Hai R, Margine I, Palese P 2013. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87:6542-6550. http://dx.doi.org/10.1128/JVI.00641-13
24. Keating R, Hertz T, Wehenkel M, Harris TL, Edwards BA, McClaren JL, Brown SA, Surman S, Wilson ZS, Bradley P, Hurwitz J, Chi H, Doherty PC, Thomas PG, McGargill MA 2013. The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol 14:1266-1276. http://dx.doi.org/10.1038/ni.2741
25. Izurieta HS, Thadani N, Shay DK, Lu Y, Maurer A, Foppa IM, Franks R, Pratt D, Forshee RA, MaCurdy T, Worrall C, Howery AE, Kelman J 2015. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis 15:293-300. http://dx.doi.org/10.1016/S1473-3099(14)71087-4
26. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, Fadel SA, Tran D, Fernandez E, Bhatnagar N, Loeb M 2013. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis BMJ 347:f5061. http://dx.doi.org/10.1136/bmj.f5061
27. O’Brien KB, Vogel P, Duan S, Govorkova EA, Webby RJ, McCullers JA, Schultz-Cherry S 2012. Impaired wound healing predisposes obese mice to severe influenza virus infection. J Infect Dis 205:252-261. http://dx.doi.org/10.1093/infdis/jir729
28. Meliopoulos VA, Karlsson EA, Kercher L, Cline T, Freiden P, Duan S, Vogel P, Webby RJ, Guan Y, Peiris M, Thomas PG, Schultz-Cherry S. 2014. Human H7N9 and H5N1 influenza viruses differ in induction of cytokines and tissue tropism. J Virol 88:12982-12991. http://dx.doi.org/10.1128/JVI.01571-14
29. Smith AG, Sheridan PA, Harp JB, Beck MA 2007. Diet-induced obese mice have increased mortality and altered immune responses when infected with influenza virus. J Nutr 137:1236-1243
30. Karlsson EA, Beck MA 2010. The burden of obesity on infectious disease. Exp Biol Med (Maywood) 235:1412-1424. http://dx.doi.org/10.1258/ebm.2010.010227
31. Callahan ST, Wolff M, Hill HR, Edwards KM, NIAID Vaccine and Treatment Evaluation Unit (VTEU) Pandemic H1N1 Vaccine Study Group 2014. Impact of body mass index on immunogenicity of pandemicH1N1 vaccine in children and adults. J Infect Dis 210:1270-1274. http://dx.doi.org/10.1093/infdis/jiu245
32. Talbot HK, Coleman LA, Crimin K, Zhu Y, Rock MT, Meece J, Shay DK, Belongia EA, Griffin MR 2012. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. Vaccine 30:3937-3943. http://dx.doi.org/10.1016/j.vaccine.2012.03.071
33. Sperling RS, Engel SM, Wallenstein S, Kraus TA, Garrido J, Singh T, Kellerman L, Moran TM 2012. Immunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartum. Obstet Gynecol 119:631-639. http://dx.doi.org/10.1097/AOG.0b013e318244ed20
34. Esposito S, Giavoli C, Trombetta C, Bianchini S, Montinaro V, Spada A, Montomoli E, Principi N 2016. Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children. Vaccine 34:56-60 http://dx.doi.org/10.1016/j.vaccine.2015.11.019
35. Richmond JY, McKinney RW III 1993. Biosafety in microbiological and biomedical laboratories. Centers for Disease Control and Prevention, Atlanta, GA
36. Del Giudice G, Rappuoli R 2014. Inactivated and adjuvanted influenza vaccines. Curr Top Microbiol Immunol 386:151-180. http://dx.doi.org/10.1007/82_2014_406
37. Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S 2006. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J Virol 80:11960-11967. http://dx.doi.org/10.1128/JVI.01678-06
38. Carlson CM, Turpin EA, Moser LA, O’Brien KB, Cline TD, Jones JC, Tumpey TM, Katz JM, Kelley LA, Gauldie J, Schultz-Cherry S 2010. Transforming growth factor-beta: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis. PLoS Pathog 6:e1001136. http://dx.doi.org/10.1371/journal.ppat.1001136
39. Morton DB 2000. A systematic approach for establishing humane endpoints. ILAR J 41:80-86. http://dx.doi.org/10.1093/ilar.41.2.80
40. World Health Organization 2011. Global Influenza Surveillance Network: manual for the laboratory diagnosis and virological surveillance of influenza. WHO, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf
41. Karlsson EA, Meliopoulos VA, Savage C, Livingston B, Mehle A, Schultz-Cherry S 2015. Visualizing real-time influenza virus infection, transmission and protection in ferrets. Nat Commun 6:6378. http://dx.doi.org/10.1038/ncomms7378
42. Jones JC, Settles EW, Brandt CR, Schultz-Cherry S 2011. Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine. Vaccine 29:7696-7703. http://dx.doi.org/10.1016/j.vaccine.2011.07.133
43. Krammer F, Margine I, Tan GS, Pica N, Krause JC, Palese P 2012. A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One 7:e43603. http://dx.doi.org/10.1371/journal.pone.0043603
44. Margine I, Palese P, Krammer F 2013. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J Vis Exp 81: http://dx.doi.org/10.3791/51112:e51112
45. Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F 2014. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol 88:13260-13268. http://dx.doi.org/10.1128/JVI.02133-14
46. Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, Del Giudice G, Rappuoli R 2011. Influenza vaccine immunology. Immunol Rev 239:167-177. http://dx.doi.org/10.1111/j.1600-065X.2010.00974.x.